Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Ic Article
This is a selection made from among articles on Drug Treatment Ic. For a permanent link to this article, or to bookmark it for future reading, click here.
from:
Drug and Alcohol Rehab
By Ken Marlborough
Rehabilitation from drug addiction is a complex process. It involves commitment from the individual addict to abstain from further drug use. The physical dependence on the drug needs to be overcome through medical intervention. Medical supervision is essential to safely detoxify an addicted individual. Safety is an issue since sudden withdrawal of a drug will lead to very profound physiological changes that can be very uncomfortable and can sometimes be life threatening. The range of drugs abused is wide but general principles apply to drug and alcohol rehabilitation.
After the medical detoxification process, which is often in an inpatient setting, a program to continue the rehab process as an outpatient is essential. Sometimes replacement drugs are needed such as methadone maintenance programs where patients are given methadone to replace the heroin that is abused. The methadone helps prevent the euphoria and at the same time decreases the craving that is central to addiction. A typical dose that may work is 30-60 milligrams of methadone daily but this is variable and depends on the intensity of addiction among other factors. Alcohol rehab often involves an acute hospital based detoxification where a thorough medical assessment is done and then drugs belonging to the class called benzodiazepines are given to prevent withdrawal. Medical issues are often the main reason an addict enters a treatment entry point.
After this acute phase an outpatient 12 step program such as Alcoholics Anonymous is critical to maintain abstinence. Many patients who are addicted to drugs have co-morbid psychiatric conditions like depression that need to be addressed. Others have HIV/AIDS, which also need to be managed if a lasting solution is needed. Many rehab programs are covered by insurance and charity. They also have social workers who will help with the practical aspects of getting back to a productive life.
Above all, the commitment of the individuals working in the program helps sustain and develop faith and trust in the system since addicts are often marginalized members of society.
Drug Rehab provides detailed information on Drug Rehab, Drug Rehab Programs, Drug Rehab Centers, Drug And Alcohol Rehab and more. Drug Rehab is affiliated with Drug Detox Rehab.
Article Source: http://EzineArticles.com/?expert=Ken_Marlborough
http://EzineArticles.com/?Drug-and-Alcohol-Rehab&id=231119
Drug Treatment Ic Specific links
Drug Treatment Ic News
Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study
Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in ...
Read more...Celldex’s CDX-011 Demonstrates High Response Rates in Patients with Metastatic Breast Cancer Expressing Elevated ...
Celldex Therapeutics, Inc. today announced preliminary results from the Company’s randomized Phase 2b EMERGE study of CDX-011 antibody drug conjugate in patients with glycoprotein NMB expressing, advanced, heavily pretreated breast cancer.
Read more...Press Release
Celldex Therapeutics Inc. Posted on:24 May 12 Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced preliminary results from the Company’s randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer.
Read more...Equity Briefing : Pluristem's PLX cells may change bone marrow transplantation as well as other potential indications
CEO of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) (TASE:PLTR) tells shareholders that his firm`s PLX cells may be effective in supporting bone marrow transplantation as well as other potential indications ...
Read more...Global Human Vaccines Industry
NEW YORK, May 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Global Human Vaccines Industry http://www.reportlinker.com/p092575/Global-Human-Vaccines-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and ...
Read more...Pluristem's CEO Letter to Shareholders
HAIFA, Israel -- Pluristem Therapeutics, Inc. today announces the below CEO letter to shareholders:
Read more...Medgenics Inc - 1st Quarter Results
Press Release 14 May 2012 Medgenics Announces First Quarter 2012 Financial Results Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel technology ...
Read more...Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child After Bone Marrow Transplantation Failure
HAIFA, Israel -- Pluristem Therapeutics, Inc. today announced that a seven year-old girl suffering from an aplastic bone marrow whose condition was rapidly deteriorating is now experiencing a reversal ...
Read more...Market overview: 30 April
• Advertising conglomerate WPP has made a small strategic investment in Enprecis, a US company which uses a proprietary online platform to collect and analyse data about consumer experience for the car industry.
Read more...Market overview: 2 May
HSBC completes sale of US card unit to Capital One; Standard Chartered reports strong first quarter; good start to the year for Spirent; plus updates on Next, Bunzl, BAE and others.
Read more...